Introduction
The haemostatic system is essential for the preservation of life. The haemostatic system protects man from exsanguination after wound injuries and also forms the basis for the numerous tissue repair processes that are believed to be constantly ongoing within the vascular bed as initially proposed by Tage Astrup more than four decades ago (Astrup, 1956 ). The haemostatic system contributes to atherogenesis and controls intravascular thrombus formation, and thus plays an important role in the development of coronary heart disease (CHD), notably acute ischaemic events (myocardial infarction, unstable angina pectoris, and sudden death), and ischaemic stroke (Fuster et al, 1992a (Fuster et al, , 1992b Falk & Ferna Ândez-Ortiz, 1995) . These diseases are dominant causes of death in industrialised countries. Accordingly, it is of utmost interest to gain insight into the haemostatic system and its possible modi®cation by internal and external factors. Such knowledge could pave the way for rational prevention of cardio-and cerebrovascular disease. The present review describes how diet affects one key protein of the haemostatic systemÐ blood coagulation factor VII (FVII)Ðand also discusses the possible mechanisms underlying the dietary control of FVII. The impact of diet on FVII and other important haemostatic factors has been discussed in several other recent reviews to which interested readers are referred for additional reading Marckmann, 1995; Mennen et al, 1996; Miller, 1996; Vorster et al, 1997; Yahia & Sanders, 1997) .
FVIIÐits role in arterial thrombosis
Formation of an arterial thrombus involves the arterial intima and the haemostatic system, namely platelets, blood coagulation factors, and the ®brinolytic system, and their complex interaction. The process is initiated by endothelial perturbation or disruption, primarily at sites of atherosclerotic plaques (Falk, 1991; Falk & Ferna Ândez-Ortiz, 1995) . The intimal perturbance causes activation of platelets and coagulation factors resulting in ®brin formation and deposition on the location. The ®brinolytic system has the ability to degrade ®brin and in¯uences the outcome by counteracting the prothrombotic processes. Accordingly, the thrombotic propensity is linked to the balance, namely the haemostatic balance, between thrombus promoters (platelets and coagulation factors) on the one side, and the thrombus-resolving ®brinolytic system on the other (Astrup, 1956 (Astrup, , 1958 Jespersen, 1988; Jespersen et al, 1993; Marckmann, 1995; Marckmann & Jespersen, 1996) .
It has been known for many years that the coagulation system can be activated in vitro by either the intrinsic (the FXII-dependent route) or the extrinsic route (the Tissue Factor (TF) pathway) (Davie et al, 1991) . Formerly, the two activation pathways were considered functionally separated, and both were considered physiologically important. However, FVII de®ciency is, whereas FXII de®ciency is not, associated with increased bleeding tendency, indicating that the FVII-dependent TF pathway is the important route in vivo. Other observations support that the TF pathway is the`prima ballerina' of the coagulation system, and also suggest that factors that were traditionally considered purely intrinsic, notably FIX, act as ampli®ers of the TF pathway under most circumstances (Hemker, 1984; ésterud, 1990; Davie et al, 1991; Nemerson, 1992; Rapaport & Rao, 1992 (Figure 1 ). The TF pathway may be particularly important in arterial thrombosis because atherosclerotic plaques have a high content of membranebound TF which becomes exposed to the¯owing blood when plaques rupture (Ardissino et al, 1997) . The ®rst step of the TF pathway is the complex formation of TF and FVII and this explains why FVII is crucial in haemostasis, in general, and in arterial thrombosis, in particular. In most situations, FVII appears to be the essential humoral initiator and trigger of ®brin formation (Rapaport & Rao, 1995; Monroe et al, 1996) .
Native and activated FVII
FVII is produced by hepatocytes and is released into the circulation in its native form, namely FVII zymogen. In this form, it is a single-chained 406 amino acid residue glycoprotein with a molecular mass of about 50 000 and a plasma half-life of 5±6 h. Vitamin K is cofactor for the posttranslational carboxylation of glutamate residues of FVII which is crucial for its ability to bind calcium ions and thus for its function (Furie & Furie, 1992) .
Native FVII protein can be converted to two-chained activated FVII (FVIIa) in vitro by thrombin, TF-FVIIa complex and activated forms of FIX, FX, and FXII. The FVII activation is strongly facilitated by binding of FVII zymogen to TF and is furthermore dependent on the presence of phospholipids, namely cell membranes (Rapaport and Rao, 1992; Petersen et al, 1995) . It is not known with certainty by which mechanisms FVII activation takes place in vivo, but some observations indicate that circulating trace amounts of FVIIa or FIXa are the principal FVII activators. Subsequently, the newly formed TF-FVIIa will attack its natural substrates, FIX and FX, resulting not only in the propagation of the clotting cascade, but also in backactivation of TF-bound unactivated FVII (Rapaport & Rao, 1995; Morrissey, 1995; Petersen et al, 1995) (Figure 1 ). Under basal conditions, FVIIa circulates at concentrations corresponding to approximately 1% of the concentration of native FVII. Its estimated half-life is 2±3 h (Seligsohn et al, 1979) .
Tissue Factor Pathway Inhibitor (TFPI) is the only known inhibitor of the TF-FVIIa complex. Following generation of FXa, TFPI ®rst binds to FXa thereby inhibiting FXa. The TFPI-FXa complex subsequently binds to TFFVIIa forming an inactive quarternary complex. Readers are referred to other reviews for further details (Abildgaard et al, 1993; Petersen et al, 1995) .
FVII assays
Various FVII assays describing different aspects of FVII are now available. It is essential that researchers are aware of the differences between these assays and that they select carefully between them according to the aim of their study. Because of the assay differences, it is extremely important that all research publications within this area contain exact information about the methodology used for FVII measurement.
The classical FVII assay is based on the ability of a test plasma to correct the clotting time of FVII de®cient plasma and measures by de®nition FVII coagulant activity (FVIIc). It is a one-stage clotting assay in which diluted test plasma is mixed with human TF, CaCl 2 , and FVII de®cient plasma (Marbet & Duckert, 1992) . The clotting time is recorded and FVIIc expressed relative to a log±log linear calibration curve based on a reference plasma. FVIIc re¯ects a combination of the plasma concentrations of FVIIa and FVII zymogen, because FVII activation takes place in the test tube during assaying. The FVIIc measurement is dependent on the quality of the FVII de®cient plasma, and, in particular, on whether the TF used for the analysis is obtained from man or other species (Poggio et al, 1991) . We consider human TF (brain or placenta) the physiologically most relevant TF for FVIIc measurements in man, but rabbit TF may be an acceptable alternative.
The concentration of FVIIa in plasma may be assessed by different methods (Kitchen et al, 1992) . Initially, FVIIa was assessed in a one-stage clotting assay similar to that used for FVIIc, the only difference being that bovine TF replaced human TF. This principle was based on observations indicating that bovine TF has a selective af®nity for FVIIa (Hemker et al, 1976; Poggio et al, 1991; Kitchen et al, 1992) . The nomenclature is somewhat confusing, but we and others have used the term FVIIbt (bt for bovine TF) for this measurement. A more speci®c assay for FVIIa was developed by Morrissey and coworkers (Morrissey et al, 1993; Morrissey, 1995) . This assay is also a one-stage clotting assay, but uses a truncated, soluble, recombinant TF, which possesses cofactor function for FVIIa. The truncated TF does not support autoactivation of FVII zymogen, however. Accordingly, FVII zymogen should not in¯uence this FVIIa measurement. Morrissey's FVIIa assay is now commercially available (Staclot 1 VII-rTF, Stago, Asnie Áres, France). A recent study compared it with the FVIIbt assay and concluded that the two methods were in good agreement (Kario et al, 1995) . Most recently, an ELISA assay based on FVIIa antibodies was introduced (Philippou et al, 1997) . According to this assay, normal plasma FVIIa concentration is below 0.1 ngamL (less than 0.002 nmolaL), whereas Morrissey's functional assay estimates that it is about 3 ngamL (0.06 nmolaL). This large difference could be explained by unexpected FVII zymogen activation in the functional assay or the fact that two different assay principles are used, but the question is unsettled.
The total FVII protein concentration (zymogen and FVIIa) in plasma may be assessed by two methods, either directly in an ELISA assay using an antihuman FVII rabbit polyclonal IgG as ®rst and second antibody, or indirectly by a functional two-stage amidolytic micro-titre assay (Coaset 1 FVII, Chromogenix, Mo Èlndal, Sweden). We recommend that FVII protein measurements are referred to as FVIIag (ag for antigen) when ELISA assays are used, and as FVIIam (am for amidolytic) when the amidolytic assay is used. The two methods should give comparable results, except if the tested plasma contains FVII or FVIIa that are functionally abnormal.
FVII and coronary heart disease
Based on the evidence presented so far, one would expect elevated plasma levels of FVII to be associated with an increased risk of arterial thrombosis. Till now, only two prospective epidemiological studies have tried to demonstrate that to be the case. The Northwick Park Heart Study (NPHS) comprised 1459 healthy middle-aged men who had their plasma FVIIc measured in non-fasting morning samples, and in that study FVIIc was indeed found to predict Figure 1 A simpli®ed hypothetical outline of blood coagulation activation in vivo. The interactions are dependent of phospholipids and are believed to take place on cell membrane surfaces. The dotted arrow represents the train of events leading from FXa downstream to ®brin formation. Readers are referred to other reviews for details (Davie et al, 1991; Rapaport & Rao, 1992) . Abbreviations: TF tissue factor; F blood coagulation factor; a activated form.
Diet and blood coagulation factor VII P Marckmann et al total and fatal CHD cases within the ®rst 5 y of follow-up (Meade et al, , 1986a . With longer follow-up periods, FVIIc was only predicting fatal CHD Ruddock & Meade, 1994) . Meade and coworkers estimated that an increase in FVIIc of 1 s.d. (approximately 25%) will increase the 5 y risk of fatal CHD with 55% (Meade et al, 1986a) . The Prospective Cardiovascular Mu Ènster (PROCAM) study is based on the measurement of plasma FVIIc in fasting blood samples of more than 2500 middleaged men without prior history of myocardial infarction or stroke. In line with NPHS, the PROCAM study showed that elevated FVIIc is associated with an increased risk of acute CHD events (fatal and non-fatal) as assessed after followup periods of 6±8 y (Heinrich et al, 1994; Assmann et al, 1996) . Ecological studies have reported that FVIIc is higher in countries where CHD is more prevalent (Meade et al, 1986b; Iso et al, 1989) . Also, CHD patients and individuals at high risk of CHD had higher plasma levels of FVIIc, FVIIa, or FVIIag than healthy controls in several casecontrol studies (Hoffman et al, 1989; Suzuki et al, 1991; Burns et al, 1993; Kario et al, 1994; Moor et al, 1995) . In other studies there were no differences between patients and controls, or even lower values among patients (Salomaa et al, 1994; Lane et al, 1996) . These inconcistencies are not easily understood, but methodologically differences between studies might contribute. Furthermore, CHD patients may have lowered their FVII levels by changes in lifestyle after having been diagnosed in some of the studies. Within groups of patients with diagnosed atherosclerosis or CHD, FVIIc is neither predicting future CHD risk nor associated with the number of diseased coronary vessels (Cortellaro et al, 1992 ; ECAT Angina Pectoris Study Group, 1993) .
In conclusion, FVIIc was shown to be an independent predictor of acute CHD events in healthy males in two separate prospective studies. It remains to be investigated whether FVIIa or FVIIag might be better predictors, and whether FVII is also a risk factor among healthy females. Apparently, FVII measurements can neither be used for prediction of future acute CHD events nor assessment of the extent of coronary atherosclerosis within populations with diagnosed CHD.
Dietary effects on FVII
FVIIs key position in the haemostatic system and CHD pathogenesis makes it important to know whether FVII is in¯uenced by environmental factors. In that case, environmental modi®cation of FVII function could contribute to prevention and treatment of CHD and other atherothrombotic diseases.
Diet and fasting FVII
The ®rst dietary trial demonstrating an effect on FVII was a single-armed intervention study in which eleven hyperlipemic men had their FVIIc assessed before and after a 1±5 month period on a low energy, low-saturated fat diet (Elkeles et al, 1980 ). An average plasma FVIIc decline of 24% was observed. Others reported similar results when non-insulin dependent diabetics or hypertriglyceridemic patients were treated with low-fat high-®ber diets for periods of 6±24 weeks (Simpson et al, 1982 , Skartlien et al, 1989 , Jennings et al, 1991 . In 1986, it was reported that FVIIc is also in¯uenced by diet in healthy subjects (Miller et al, 1986) . In this study, prescribed highfat (62 En% from fat) and low-fat (13 En%) diets were followed for periods of 2±3 weeks by six volunteers, and FVIIc was found to be 16% higher on the high-fat diet. The authors suggested that the FVIIc effect was primarily due to the dietary differences in fat content. The prescribed diets differed also in several other aspects (for example total energy, alcohol, and dietary ®ber contents), however. Later observations have indicated that the independent effect of the total fat content may be very limited and that complex dietary changes are required to obtain an effect on fasting FVIIc (Marckmann et al, 1992a . In our ®rst trial, the experimental low-fat high-®ber diets caused a signi®cant 11±15% lowering of FVIIc compared with the moderately high-fat diets habitually eaten (Marckmann et al, 1990) . The same study demonstrated that the effect on fasting FVIIc was due to a change in the total FVII protein concentration (FVIIag) with proportionate changes in FVIIbt. Other studies con®rmed that diets corresponding to current dietary recommendations, namely low in total fat content and high in ®ber, may lower healthy individuals' fasting FVIIc by 5±15% compared with the type of diet eaten in most industrialized societies (Marckmann et al, 1993a Brace et al, 1994) . Two larger studies of freeliving individuals were unable to con®rm the FVIIc lowering effects seen in more strictly controlled dietary studies, however (Anderssen et al, 1995; Velthuis-te Wierik et al, 1996) . Their negative results might re¯ect an insuf®cient compliance with the dietary protocols which is supported by the absence of expected body weight and blood lipid changes in the two studies.
Blood lipids, in particular LDL cholesterol concentrations, are strongly affected by the fatty acid composition of the diet. Several trials have investigated whether fasting FVII levels also are modi®ed by the dietary fat quality. The issue is not fully resolved, but at present it may be concluded thatÐwith few possible exceptionsÐthere is no effect of the dietary fatty acid composition. In one of the earliest studies, strictly controlled diets rich in either monounsaturated (MUFA) or polyunsaturated fatty acids (PUFA) were consumed in random order for periods of 23 d by 38 young, healthy volunteers (Heinrich et al, 1990) . Plasma FVIIc was similar on the the two diets. We compared diets rich in either saturated fatty acids (SFA) or n-6 PUFA in two separate studies and concluded that the exchange of dietary fat had no effect on neither FVIIc, FVIIbt, nor FVIIag (Marckmann et al, 1990 (Marckmann et al, , 1992b . Similar conclusions were reached in a study in which the intake of SFA and n-6 PUFA differed more markedly (Miller et al, 1991) . In agreement herewith, one study showed that dietary counseling aiming at decreasing saturated and increasing polyunsaturated fat intake had no effect on FVIIc (Rankinen et al, 1994a) . In a strongly designed study from New Zealand, 6±8 weeks on high fat diets enriched with either SFA (dairy and coconut products), MUFA (olive and rapeseed oil), or n-6 PUFA (sun¯ower oil and margarine) resulted in similar FVIIc levels, whereas expected differences in blood lipids were seen (Foley et al, 1992) . Two recent studies compared fats high in trans fatty acids with fats with a low content of trans isomers and found no differences with respect to FVIIc (Almendingen et al, 1996; Mutanen & Aro, 1997) . Also, marine n-3 fatty acids seems to have no effect on FVII levels (Schmidt et al, 1990 (Schmidt et al, , 1992 Marckmann et al, 1991 Marckmann et al, , 1997a ésterud et al, 1995; reviewed in: Marckmann, 1995) . Most previous trials thus agree that the dietary fatty acid composition has no effect on fasting FVII levels. Single exceptions are found. Shea fat rich in stearic acid reduced FVIIc 15±20% as compared with fats high in either palmitic acid (palm oil) or a combination of lauric and myristic acid (palmkernel and high-oleic acid sunower oil mixture) in one study (Tholstrup et al, 1994a) . As underlined in the original article, this effect might have been caused by non-glyceride components of shea fat, and this certainly seems to be the most likely explanation in the light of later reports (Almendingen et al, 1996; Mutanen & Aro, 1997) . In another study, small FVIIc differences (2%) between fats rich in either palmitic (palm oil) or myristic acid (synthetic fat) were found (Tholstrup et al, 1994b) . Finally, one study reported that a SFA-rich high-fat diet is associated with higher FVIIc, FVIIag, and FVIIa levels than a n-6 PUFA-rich high-fat diet (Mitropoulos et al, 1994) . We would suggest that the low number of participants (®ve) and limited dietary control of this study might have led to the con¯icting ®nding by chance.
Few intervention trials investigated the independent effect of other dietary components. The effect of increasing dietary ®ber from 2±4 gaMJ at a ®xed intake of carbohydrate and fat by exchanging low-®ber with high-®ber foods in a mixed diet had no effect in one unpublished study from our department. However, dietary supplementation with large amounts of oat bran (10 gaMJ) rich in soluble bglucans caused a signi®cant decline in FVIIc in another strictly controlled cross-over study of 12 young males (Figure 2 ) . Coffee and caffeine seems to have no effect on FVIIc (Bak et al, 1990) .
It may be concluded that fasting FVIIc can be lowered 5±25% by a dietary change from a high-fat Western diet to a low-fat diet high in dietary ®ber (Table 1) . A change of this magnitude may modify CHD risk markedly according to epidemiological studies. The available evidence suggests that the effect on FVIIc of a change from a high-fat to a low-fat high-®ber diet cannot be attributed to one single dietary component, in particular neither to fat quantity nor quality (Marckmann & Jespersen, 1996) . Shea fat, an uncommon fat in Western countries, might have a unique ability to lower FVIIc which may be unrelated to its fatty acid composition. Finally, dietary supplementation with large amounts of oat bran might reduce FVIIc. The effect of shea fat and oat bran supplementation needs to be con®rmed, however. Dietary effects on fasting FVIIc seems primarily explained by changes in the plasma concentration of FVII protein concentration with proportionate changes in FVII zymogen and FVIIa.
Meals and postprandial FVII
Zilversmit made the point that man is mostly non-fasting and that non-fasting biochemical events have a strong impact on human (patho)physiology, including atherogenesis and thrombogenesis (Zilversmit, 1979) . This prompted the initiation of numerous postprandial studies, amongst which some focused on FVII.
Miller and coworkers were the ®rst to report an effect of diet composition on postprandial FVIIc (Miller et al, 1986) . They found that meals to which fat was added led to markedly higher FVIIc levels in the afternoon than meals added carbohydrates. Several later studies have con®rmed that high-fat meals cause a postprandial increase in FVIIc relative to isoenergetic low-fat meals (Marckmann et al, 1993b; Salomaa et al, 1993; Bladbjerg et al, 1994; Sanders et al, 1996; Larsen et al, 1997) . These studies also showed that the fat-induced FVIIc increase is caused by higher concentrations of FVIIa, whereas postprandial FVIIag pro®les are virtually similar for low-and high-fat meals. Typical postprandial pro®les of FVIIc, FVIIa and FVIIag after isoenergetic high-and lowfat meals are depicted in Figure 3 . The difference between diets is most apparent during late afternoon and early evening.
A few studies have elucidated the effect of different fats and fatty acids on postprandial FVII levels. Diets high in either SFA or n-6 PUFA were similar with respect to fasting and non-fasting FVIIc and FVIIag in the ®rst report on this issue (Miller et al, 1991) . Later studies also found that SFA and n-6 PUFA cause similar postprandial FVII pro®les (Salomaa et al, 1993; Freese & Mutanen, 1995) . Monounsaturated fats (rapeseed and olive oil) seem to share the acute FVII activating effect with other common fats (Freese & Mutanen, 1995; Sanders et al, 1996; Roche & Gibney, 1997; Larsen et al, 1997) . As an exception, triglycerides of medium chained fatty acids do not raise postprandial FVIIc and FVIIa (Sanders et al, 1996) . One study compared the effect of stearic and myristic acid and found no signi®cant differences (Tholstrup et al, 1996) . A Figure 2 Individual and median fasting FVIIc (%) of 12 young men after 16 d consumption of two strictly controlled diets served in random order. The two diets were identical except for their dietary ®ber content. The low®ber diet (LOW) contained 2.5 gaMJ, the oat-bran diet (OAT) 3.8 g ®beraMJ. The difference was achieved by the incorporation of 10 g oat branaMJ into the oat-bran diet . *P`0.05. Exchanging high-fat diet with low-fat high-®ber diet: 5±25% reduction Exchanging habitual fat with shea fat: 15±20% reduction? Incorporating large amounts of oat bran into the diet: 5±10% reduction?
? Only shown in exploratory studies, needs con®rmation.
Diet and blood coagulation factor VII P Marckmann et al single study indicated that there was no acute in¯uence of varying the ®ber content of meals from 2±4 gaMJ on postprandial FVII levels (Marckmann et al, 1993b) . Contrary to what was concluded regarding the effect of a dietary change on fasting FVIIc, the link between meal composition and postprandial FVII pro®les seems to be strongly in¯uenced by one single component, namely the total fat content of the meal. Increasing the total fat content leads to more extensive postprandial FVII activation, irrespective of the type of fat used. Fats composed of medium chained fatty acids seems to be the only exception, which may be related to the fact that medium chained fatty acids are not transported by chylomicrons but go directly to the liver via the portal vein.
Diet and FVII in epidemiological studies
Experimental studies provide the de®nitive proofs regarding diet and FVII, but epidemiological observations may support these ®ndings or suggest hitherto unknown relations. A series of cross-sectional studies investigated the relation between total dietary fat and FVIIc. These studies all share the problem of getting valid estimates of individual dietary intakes. Nevertheless, several trials suggested that total fat intake was positively associated with FVIIc Connelly et al, 1993; Va Èisa Ènen et al, 1995) . Others were unable to con®rm it, however (Rankinen et al, 1994b; Mutanen et al, 1995; Bijnen et al, 1996) . Very recently, Mennen and coworkers published an outstanding epidemiological study on diet and FVIIc (Mennen et al, 1997) . It was based on dietary assessments and FVIIc measurements of 3007 elderly individuals of both sexes. The dietary assessment methods (semiquantitative foodfrequency questionnaire) was of high quality and allowed the estimation of other aspects of the diet than just total fat intake. Mennen and coworkers concluded that total and monounsaturated fat intakes were positively associated with FVIIc only in women, that saturated fat intake was positively associated with FVIIc in both sexes, that polyunsaturated fat intake was inversely associated with FVIIc in men only, and that the dietary ®ber content was strongly and inversely associated with FVIIc.
The relation between dietary fatty acid composition as estimated from the plasma phospholipid fatty acid composition and FVIIc was studied in 2207 healthy middle-aged individuals (Folsom et al, 1994) . A positive association between the saturated fatty acid content of phospholipids and FVIIc, and an inverse relationship between linoleic acid and FVIIc was observed. In a similar study, Girelli and coworkers found a positive association between plasma lipid contents of saturated fatty acids, notably stearic acid, and FVIIc (Girelli et al, 1996) . Vegetarianism has been studied by two groups and they reached con¯icting conclusions Pan et al, 1993) . Finally, one study suggested that FVIIc is inversely associated with the intake of vitamin C as assessed from serum ascorbate concentrations (Khaw & Woodhouse, 1995) .
Overall, the epidemiological studies support the existence of a link from diet to FVIIc. Their ®ndings must be cautiously interpreted, however. Several of the observed associations might be explained by underlying covariance between speci®c nutrients and certain dietary patterns (for example those with high saturated fat intake might be those eating high-fat diets with a low ®ber content). As stated earlier, the ®nal evidence comes from controlled dietary studies.
Possible mechanisms explaining dietary effects on FVII
Dietary modi®cation of fasting FVIIc may occur within 10± 14 d after a dietary change due to changes in the plasma concentration of FVII protein (FVIIag) with proportionate changes in FVII zymogen and FVIIa (Miller et al, 1986 (Miller et al, , 1995 Marckmann et al, 1990 Marckmann et al, , 1991 Bladbjerg et al, 1995) . In contrast, FVIIa changes seems to explain the entire acute and transient dietary effect on postprandial FVIIc in meal studies (Marckmann et al, 1993b; Salomaa et al, 1993; Bladbjerg et al, 1994; Silveira et al, 1994a; Miller et al, 1996a; Kapur et al, 1996) . The mechanisms explaining acute and longer term dietary effects on FVIIc may, accordingly, differ.
Fasting plasma triglyceride concentrations correlate positively with FVIIc and FVIIag in most studies (reviewed Diet and blood coagulation VII P Marckmann et al in : Miller, 1993; Marckmann, 1995; Mennen et al, 1996) and treatment of hyperlipidaemia causes a reduction in FVIIc (Elkeles et al, 1980; Simpson et al, 1983) . The association between triglyceride-rich lipoproteins (TRLP) and FVIIc seems particularly strong (Mitropoulos et al, 1989a) . Furthermore, FVIIag seems to co-vary with the plasma concentration of other vitamin K-dependent coagulation factors (Constantino et al, 1977; Burns et al, 1993; Hoffman et al, 1994; Bladbjerg et al, 1995) . These observations indicate that dietary modi®cation of FVIIag and fasting FVIIc may be mediated through TRLP as part of a general effect on vitamin K dependent proteins. Two different mechanisms explaining this link have been proposed. Firstly, elevated plasma concentrations of TRLP might cause accentuated FVII activation leading to raised prothrombin fragment 1 2 (F1 2) generation which might ®nally increase the hepatic synthesis of vitamin K dependent proteins. This hypothesis is based on a rabbit experiment in which intravenous injection of F1 2 fragments was associated with a transient increase in the plasma concentrations of prothrombin and FX, both vitamin K-dependent proteins (Mitropoulos & Esnouf, 1990) . The ®nding that accentuated FVII activation is not associated with increased F1 2 generation in healthy humans is in con¯ict with it, however. The other hypothesis is based on experiments showing that FVII and FX adhere to TRLP (chylomicrons and VLDL) which might make them less available for catabolic degradation, thus raising their plasma concentration (Sousa et al, 1988 (Sousa et al, , 1989 . This hypothesis is challenged by the fact that patients with lipoprotein lipase (LPL) de®ciency and massive hypertriglyceridaemia have normal FVIIag levels (Mitropoulos et al, 1992) . Both hypotheses are further challenged by the fact that dietary changes in fasting triglycerides and FVIIc may be dissociated or even opposed (Schmidt et al, 1990 (Schmidt et al, , 1992 Marckmann et al, 1993a .
High-fat meals causing postprandial hypertriglyceridemia are associated with acute FVII activation. It is therefore tempting to suggest that TRLP or products of TRLP lipolysis are causally involved in postprandial FVII activation. The ®rst study in this ®eld reported that postprandial triglyceride peak concentrations correlated with FVIIc peaks 180 min later, indicating that postprandial FVII activation is somehow controlled by the triglyceride concentration (Miller et al, 1991) . Several others tried to con®rm that postprandial triglycerides and FVIIa correlate, but their ®ndings have been inconsistent (Marckmann et al, 1933b; Salomaa et al, 1993; Bladbjerg et al, 1994; Silveira et al, 1994a Silveira et al, , 1994b Silveira et al, , 1996 Kapur et al, 1996; Larsen et al, 1997) .
In vitro studies indicate that lipolysis of TRLP promotes the activation of FXII to FXIIa (Mitropoulos & Esnouf, 1991; Mitropoulos et al, 1989b Mitropoulos et al, , 1992 Mitropoulos et al, , 1993 . Subsequently, FXIIa might cleave single-chain FVII to FVIIa, thus forming the link from postprandial plasma triglycerides to FVIIa. Mitropoulos and coworkers put special emphasis on the fatty acid composition of TRLP because their studies showed that micelles of long-chained SFA were far better FXII activators than unsaturated fatty acids (Mitropoulos & Esnouf, 1991) . According to their hypothesis TRLP lipolysis leads to the formation of intravascular micelles of unbound albumin-free fatty acids that provide the negatively charged surface necessary for FXII activation. Although attractive, it is strongly contradicted by certain biochemical studies and human observations. Biochemically, the accumulation of unbound fatty acids at a concentration suf®ciently high to allow micelle formation seems unlikely due to the very high af®nity of albumin for unbound fatty acids (Bojesen & Bojesen, 1996) . In addition, recent trials showed that high-fat meals lead to FVII activation even in FXII-de®cient individuals (Miller et al, 1996a; Silveira et al, 1996) . The same studies underscored that FIX is required for postprandial FVII activation which is in line with the current perception of the initiating steps in the activation of blood coagulation (cf. Figure 1) .
Intravenous infusions of fat emulsions may lead to increased expression of TF activity by monocytes (Lattanzio et al, 1984) . This ®nding indicates that TRLP might in¯uence the availability of TF required for FVII activation and offers an alternative hypothetical link from TRLP to FVIIa. This possibility should be further investigated.
Non-dietary factors and FVII
Plasma FVII levels are in¯uenced by several other factors besides diet. It is not possible to discuss these other factors in detail within the limits of the present review, but some points can be made. Plasma FVIIc increases with age (Brozovic et al, 1974; Balleisen et al, 1985; Folsom et al, 1991) . Body weight and body mass index are also positively associated with FVIIc (Balleisen et al, 1985; Folsom et al, 1991) , and FVIIc declines when obese individuals loose weight (Folsom et al, 1993) . Smoking seems to have no in¯uence (Balleisen et al, 1985; Folsom et al, 1991) . Pregnancy is associated with markedly elevated FVIIc (Dalaker, 1986) , whereas oral contraceptives and postmenopausal hormone replacement therapy seems to raise FVIIc more moderately (Folsom et al, 1991) . Postmenopausal women have higher FVIIc levels than premenopausal women of same age . There are only minor FVIIc differences between sexes in population surveys (Brozovic et al, 1974; Balleisen et al, 1985) . However, previous dietary trials included mostly men and an interaction between diet and gender with respect to FVIIc cannot be excluded. Ethnic differences have been reported, but they may be explained by differences in lifestyle and genetic constitution (Meade et al, 1986b; Iso et al, 1989) .
The FVII gene is located on chromosome 13 (Ott & Pfeiffer, 1984) . Several mutations have been identi®ed, but only the R353Q and promoter polymorphisms seem to be frequent and functionally important. The R353Q polymorphism is located in exon 8 of the FVII gene. It is caused by a single base change from guanine to adenine in the codon for aminoacid residue 353 of native FVII protein, leading to the replacement of arginine (R) with glutamine (Q). The Q allele frequency ranges from 0.03±0.29 in different populations. Heterozygous individuals (RQ) have approximately 25% lower plasma levels of FVIIc, FVIIag, and FVIIa than RR individuals (Green et al, 1991; Lane et al, 1992; Saha et al, 1994; Moor et al, 1995; Bentzen et al, 1996; Bernardi et al, 1996) . The promoter polymorphism is caused by a 10 base pair insertion in the promoter region. The frequency of the rare P10 allele is similar to the Q allele of the R353Q polymorphism with which its also shows strong allelic association. Similar to the Q allele, the P10 allele is associated with lower FVIIc, FVIIag, and FVIIa levels, and the P10 allele might be the stronger determinant of low FVII levels of the two Bernardi et al, 1996) .
The ®nding that the positive association between fasting plasma triglycerides and FVIIc is con®ned to the RR genotype and weaker or absent among individuals carrying the Q allele of the R353Q polymorphisms suggests an interaction between gene and environment (Lane et al, 1992; Humphries et al, 1994) . This possibility can be explored in dietary trials of individuals with different FVII genotypes. The ®rst studies indicate that RQ individuals respond in the same way as RR individuals to fatty meals, although at a lower level (Silveira et al, 1994b; Marckmann et al, 1997b) .
Physiological impact of FVII
Plasma FVII de®ciency causes severe bleeding, and FVIIa infusions may correct increased bleeding tendency not only in cases of FVII de®ciency, but also in classical Hemophilia A and B (Mariani & Mazzucconi, 1983; Lusher, 1996; Bauer, 1996) . These ®ndings demonstrate the importance of FVII in haemostasis. The impact of FVIIc in human thrombogenesis was suggested by the ®nding of positive associations between FVIIc and prothrombin fragment 1 2 (F1 2) (Miller et al, 1996b; Gouin-Thibault et al, 1996) , and by the rise in F1 2 that follows infusion of recombinant FVIIa in FVII-de®cient patients . More direct evidence comes from animal experiments showing that inhibition of the TF pathway causes less ®brin formation and thrombogenesis following intimal injuries of the arteries (Speidel et al, 1996; Jang et al, 1995; Arnljots et al, 1997) .
An important question is whether dietary modi®cation of FVII affect in vivo thrombin generation and ®brin formation or whether dietary FVII changes are counterbalanced by some mechanism. This may be assessed by the measurement of split products of prothrombin and ®brino-gen. The question has only been addressed in few studies. One study reported that dietary lowering of fasting FVIIc and FVIIag was accompanied by a decrease in F1 2 (Bladbjerg et al, 1995) . This observation contrasts with those of two meal studies in which F1 2 levels were not affected by acute postprandial FVII activation (Silveira et al, 1996; Kapur et al, 1996) . All three studies included healthy volunteers with F1 2 concentrations very close to the detection limit. Furthermore, it should be considered that an increase in FVIIc, FVIIag, andaor FVIIa may rather represent a state of increased`readiness' of the coagulation system than of increased thrombin formation. Major bursts of thrombin formation is dependent on local catastrophies of the arterial intima and massive TF exposure which are unlikely to occur in healthy individuals. Therefore, we suggest that future studies investigate the consequences of dietary modi®cation of FVII in individuals at high risk of thrombosis, such as CHD patients with coronary atherosclerosis.
Conclusions and perspectives
The current understanding of the haemostatic system places FVII in a key position. In agreement herewith, epidemiologic data indicate that raised plasma levels of FVIIc promote coronary thrombosis. Dietary modi®cation of FVIIc might thus have a role in the prevention of CHD. We want to emphasize that the impact of diet on FVIIc is not tightly linked to its plasma lipid effects. This means that the speci®c link between diet and FVII needs to be taken into account when optimal diets for the prevention of CHD and other thrombotic diseases are discussed. Further studies elaborating the impact of diet on FVII and, in particular, the impact of dietary FVII modi®cation on thrombin generation are highly warranted. The amazing ®ndings in trials where diet was used for secondary prevention of CHD could not be explained by effects on traditional risk factors and might be related to dietary modi®cation of key components of the haemostatic system, not the least of FVII (Singh et al, 1992; de Lorgeril et al, 1994) . Hopefully, future studies of this kind will include the measurement of FVII.
